TITLE

A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease

AUTHOR(S)
Grace, J.; Amick, M. M.; Friedman, J. H.
PUB. DATE
January 2009
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jan2009, Vol. 80 Issue 1, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To study the efficacy and safety of galantamine hydrobromide ER for the enhancement of cognition in non-demented Parkinson's patients (PD). Methods: Sixty-nine non-demented PD participants were randomised in a double-blind, placebo-controlled study of galantamine or placebo. Galantamine was administered over 16 weeks (8 mg/day for 4 weeks, a therapeutic dose of 16 mg/day for 6 weeks and a maximum dose of 24 mg/day for 6 weeks). Outcome measures were neuropsychological (attention, verbal fluency, executive, memory, visuospatial), behavioural (Frontal Systems Behavior Scale, Neuropsychiatric Inventory-Questionnaire, PDQ-39) and motor (Unified Parkinson's Disease Rating Scale motor scale). Results: 26 individuals on active medication and 28 individuals on placebo were included in the outcome analyses. No significant differences were found between the active and placebo groups on cognitive, behavioural or motor outcome measures. Most common adverse events were gastrointestinal and self-reported worsening of PD symptoms. Conclusions: Contrary to our hypotheses, galantamine treatment did not improve attention/executive, memory or visuospatial performance in non-demented PD patients. Further, there was a high, statistically significant drop-out rate in the treatment group due to gastrointestinal side effects and self-reported worsening of PD symptoms. Treatment with galantamine did not enhance self- perception of mental sharpness or quality of life. No negative behavioural change such as hallucinations or apathy was found with treatment.
ACCESSION #
36132252

 

Related Articles

  • Side of onset in Parkinson's disease and alterations in religiosity: Novel behavioral phenotypes. Butler, Paul M.; McNamara, Patrick; Durso, Raymon // Behavioural Neurology;2011, Vol. 24 Issue 2, p133 

    Behavioral neurologists have long been interested in changes in religiosity following circumscribed brain lesions. Advances in neuroimaging and cognitive experimental techniques have been added to these classical lesion-correlational approaches in attempt to understand changes in religiosity due...

  • Tiefe Hirnstimulation mittels simultaner stereotaktischer Elektrodenplatzierung. Matzke, C.; Hammer, N.; Weise, D.; Lindner, D.; Fritzsch, D.; Classen, J.; Meixensberger, J.; Winkler, D. // Der Nervenarzt;Dec2014, Vol. 85 Issue 12, p1561 

    Background: Deep brain stimulation (DBS) has become a reliable method in the treatment of movement disorders, e.g. idiopathic Parkinson's disease (IPD) and is technically based on stereotaxy. The Starfix® platform is a new type of stereotactic frame that allows an individualized and...

  • Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study. Verschuur, Constant V. M.; Suwijn, S. R.; Post, B.; Dijkgraaf, M.; Bloem, B. R.; van Hilten, J. J.; van Laar, T.; Tissingh, G.; Deuschl, G.; Lang, A. E.; de Haan, R. J.; de Bie, R. M. A. // BMC Neurology;11/19/2015, Vol. 15 Issue 1, p1 

    Background: The aim of this study is to investigate if early treatment with levodopa has a beneficial disease modifying effect on Parkinson's disease (PD) symptoms and functional health, improves the ability to (maintain) work, and reduces the use of (informal) care, caregiver...

  • Pramipexole Extended Release. Chwieduk, Claudine M.; Curran, Monique P. // CNS Drugs;2010, Vol. 24 Issue 4, p327 

    Pramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson's disease. Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have...

  • Management of Motor and Non-Motor Symptoms in Parkinson's Disease. Sprenger, Fabienne; Poewe, Werner // CNS Drugs;2013, Vol. 27 Issue 4, p259 

    Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects approximately 1 % of people over the age of 60 years. Accurate diagnosis and individualized assessment of the risks and benefits of available antiparkinsonian medications as well as specific clinical...

  • Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson 's Disease. Martinez-Martin, Pablo; Rodriguez-Blazquez, Carmen; Forjaz, Maria; Kurtis, Monica // CNS Drugs;May2015, Vol. 29 Issue 5, p397 

    Quality of life (QoL) is a patient-reported outcome frequently included in Parkinson's disease (PD) clinical trials as a secondary or tertiary endpoint. However, QoL is an important variable that reflects the impact of disease and treatment from the patients' perspective. In a chronic,...

  • The role of the right dorsolateral prefrontal cortex in the Tower of London task performance: repetitive transcranial magnetic stimulation study in patients with Parkinson's disease. Srovnalova, H.; Marecek, R.; Kubikova, R.; Rektorova, I. // Experimental Brain Research;Nov2012, Vol. 223 Issue 2, p251 

    We studied whether one session of high-frequency repetitive transcranial magnetic stimulation (rTMS) applied over either the right or left dorsolateral prefrontal cortex would induce any measurable changes in the Tower of London spatial planning task performance in patients with Parkinson's...

  • Bilateral subthalamic nucleus stimulation in advanced Parkinson’s disease: Five year follow-up. Gervais-Bernard, Hélène; Xie-Brustolin, Jing; Mertens, Patrick; Polo, Gustavo; Klinger, Hélène; Adamec, Dario; Broussolle, Emmanuel; Thobois, Stéphane // Journal of Neurology;Feb2009, Vol. 256 Issue 2, p225 

    To assess the long-term efficacy and safety of bilateral subthalamic nucleus (STN) stimulation in patients with advanced Parkinson’s disease (PD). 42 consecutive patients with idiopathic PD treated with bilateral STN stimulation were enrolled. Parkinsonian status, medication intake and...

  • Short- and long-term effects of tactile massage on salivary cortisol concentrations in Parkinson's disease: a randomised controlled pilot study. Törnhage, Carl-Johan; Skogar, Örjan; Borg, Astrid; Larsson, Birgitta; Robertsson, Laila; Andersson, Lena; Lena Andersson; Backstrom, Paulina; Fall, Per-Arne; Hallgren, Gunnar; Bringer, Birgitta; Carlsson, Miriam; Lennartsson, Ulla Birgitta; Sandbjörk, Håkan; Lökk, Johan // BMC Complementary & Alternative Medicine;2013, Vol. 13 Issue 1, p357 

    Background: Parkinson’s disease (PD) is a chronic neurodegenerative disorder with limited knowledge about the normal function and effects of non-pharmacological therapies on the hypothalamicpituitary- adrenal (HPA) axis. The aim of the study was to analyse the basal diurnal and total...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics